Patents by Inventor Udo Stropp

Udo Stropp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted &agr;, &bgr;-anellated butyrolactones
    Patent number: 6723718
    Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: April 20, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Substituted alpha, beta-anellated butyrolactones
    Publication number: 20030158424
    Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Application
    Filed: July 25, 2002
    Publication date: August 21, 2003
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Muller, Jorg Baumgarten, Karsten von dem Bruch, Gerhard Muller, Udo Stropp, Ervin Horvath, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Substituted &agr;, &bgr;-anellated butyrolactones
    Patent number: 6462074
    Abstract: The present invention relates to novel substituted (&agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: October 8, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Substituted &bgr;,&ggr;-anellated lactones
    Patent number: 6433004
    Abstract: The present invention relates to novel substituted &bgr;,&ggr;-fused lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: August 13, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Substituted bicyclic lactones
    Patent number: 6376539
    Abstract: The present invention relates to novel substituted bicyclic lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, cranial cerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: April 23, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Nucleic acid-binding oligomers for therapy and diagnosis
    Patent number: 5955571
    Abstract: The present invention relates to compounds of the general formula (I), ##STR1## in which the radicals have the meaning given in the description, to processes for their preparation and to their use as medicaments.
    Type: Grant
    Filed: August 1, 1995
    Date of Patent: September 21, 1999
    Assignee: Bayer Aktiengesellschaft
    Inventors: Christoph Schwemler, Thorsten Potter, Burkhard Mielke, Eckhard Schwenner, Axel Kretschmer, Udo Stropp, Winfried Kosch, Hansjorg Durr
  • Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics
    Patent number: 5849893
    Abstract: The invention relates to nucleic acid-binding oligomers possessing C-branching of the general formula (I) ##STR1## and to the corresponding monomers, whose radicals have the meaning given in the description, and to their use as medicaments or diagnostic aids.
    Type: Grant
    Filed: September 24, 1996
    Date of Patent: December 15, 1998
    Assignee: Bayer Aktiengesellschaft
    Inventors: Antonius Lobberding, Burkhard Mielke, Christoph Schwemler, Eckhard Schwenner, Udo Stropp, Wolfgang Springer, Axel Kretschmer, Thorsten Potter
  • Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics
    Patent number: 5623049
    Abstract: The invention relates to nucleic acid-binding oligomers possessing N-branching of the general formula (I), ##STR1## and their monomers, where the individual radicals have the meaning given in the description, and to their use as medicaments or as aids in diagnostics.
    Type: Grant
    Filed: September 6, 1994
    Date of Patent: April 22, 1997
    Assignee: Bayer Aktiengesellschaft
    Inventors: Antonius L obberding, Burkhard Mielke, Christoph Schwemler, Eckhard Schwenner, Udo Stropp, Wolfgang Springer, Axel Kretschmer, Thorsten P otter
  • HIV antisense expression vectors
    Patent number: 5583035
    Abstract: The present invention relates to the targeted blocking of the genetic information of the viral messenger ribonucleic acid (mRNA) for virus replication (e.g. of HIV) in transfected, haematopoietic cells with particularly suitable expression systems, which express a complementary "antisense RNA".
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: December 10, 1996
    Assignee: Bayer Aktiengesellschaft
    Inventors: Axel Kretschmer, Horst-Peter Antonicek, Jorg Baumgarten, Antonius Loebberding, Burkhard Mielke, Wolfgang Springer, Udo Stropp, Mark-Michael Struck, Lothar Biesert, Helga Rubsamen-Waigmann, Hary Suhartono, Thomas-Peter Hausner
  • Oligophosphates with an antiviral action
    Patent number: 5169842
    Abstract: Novel oligophosphates with an antiviral action of the formula ##STR1## in which n is 3-50,B and E are, independently of one another, O, S or NH,A is O, NR or S,D is O, S or NR.sub.2, in which independently each R is H, alkyl, aralkyl or aryl,andX is --(CH.sub.2).sub.
    Type: Grant
    Filed: May 9, 1991
    Date of Patent: December 8, 1992
    Assignee: Bayer Aktiengesellschaft
    Inventors: Antonius Lobberding, Axel C. Heitmann, Burkhard Mielke, Udo Stropp, Axel Kretschmer, Helga Rubsamen-Waigmann, Lothar Biesert, Haryadi Suhartono